Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment.

ABSTRACT:

Background

We evaluated the palatability and acceptability of a 100 mg dispersible and a non-dispersible 250 mg levofloxacin (LVX) tablet formulation in children.

Methods

Perform was a randomised, open-label, cross-over trial of the relative bioavailability of LVX dispersible vs. crushed non-dispersible tablets in children aged <6 years routinely receiving TB preventive treatment. Children and caregivers completed Likert- and ranking-type measures on the acceptability of both formulations. We used summary, comparative and ranking statistics to characterise formulation acceptability.

Results

A total of 25 children were enrolled (median age: 2.6 years, IQR 1.6-4.0). Caregivers reported frequent challenges with preventive therapy in routine care prior to study entry, inc

SUBMITTER: Wademan DT 

PROVIDER: S-EPMC11221592 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature